These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 28426825)
1. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. Gandhi RT; McMahon DK; Bosch RJ; Lalama CM; Cyktor JC; Macatangay BJ; Rinaldo CR; Riddler SA; Hogg E; Godfrey C; Collier AC; Eron JJ; Mellors JW; PLoS Pathog; 2017 Apr; 13(4):e1006285. PubMed ID: 28426825 [TBL] [Abstract][Full Text] [Related]
2. Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy. Blazkova J; Whitehead EJ; Schneck R; Shi V; Justement JS; Rai MA; Kennedy BD; Manning MR; Praiss L; Gittens K; Wender PA; Oguz C; Lack J; Moir S; Chun TW J Infect Dis; 2024 Jun; 229(6):1770-1780. PubMed ID: 38128541 [TBL] [Abstract][Full Text] [Related]
3. Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy. Christensen-Quick A; Massanella M; Frick A; Rawlings SA; Spina C; Vargas-Meneses M; Schrier R; Nakazawa M; Anderson C; Gianella S J Virol; 2019 Jul; 93(13):. PubMed ID: 31019052 [TBL] [Abstract][Full Text] [Related]
4. Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy. Cyktor JC; Bosch RJ; Mar H; Macatangay BJ; Collier AC; Hogg E; Godfrey C; Eron JJ; McMahon DK; Mellors JW; Gandhi RT; J Infect Dis; 2021 Feb; 223(3):462-470. PubMed ID: 32603416 [TBL] [Abstract][Full Text] [Related]
5. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299 [TBL] [Abstract][Full Text] [Related]
6. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. Gandhi RT; Cyktor JC; Bosch RJ; Mar H; Laird GM; Martin A; Collier AC; Riddler SA; Macatangay BJ; Rinaldo CR; Eron JJ; Siliciano JD; McMahon DK; Mellors JW; J Infect Dis; 2021 Feb; 223(2):225-233. PubMed ID: 32823274 [TBL] [Abstract][Full Text] [Related]
7. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART. Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. Jain V; Hartogensis W; Bacchetti P; Hunt PW; Hatano H; Sinclair E; Epling L; Lee TH; Busch MP; McCune JM; Pilcher CD; Hecht FM; Deeks SG J Infect Dis; 2013 Oct; 208(8):1202-11. PubMed ID: 23852127 [TBL] [Abstract][Full Text] [Related]
9. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK; AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509 [TBL] [Abstract][Full Text] [Related]
10. Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. Eller MA; Hong T; Creegan M; Nau ME; Sanders-Buell E; Slike BM; Krebs SJ; Ratto-Kim S; McElrath MJ; Katabira ET; Bolton DL; Michael NL; Robb ML; Tovanabutra S; Baeten JM; Sandberg JK AIDS; 2020 Feb; 34(2):197-202. PubMed ID: 31764072 [TBL] [Abstract][Full Text] [Related]
11. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Besson GJ; Lalama CM; Bosch RJ; Gandhi RT; Bedison MA; Aga E; Riddler SA; McMahon DK; Hong F; Mellors JW Clin Infect Dis; 2014 Nov; 59(9):1312-21. PubMed ID: 25073894 [TBL] [Abstract][Full Text] [Related]
13. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. Bedimo RJ; Mar H; Bosch RJ; Drechsler H; Cyktor JC; Macatangay BJC; Lalama C; Rinaldo C; Collier A; Godfrey C; Hogg E; Hensel C; Eron JJ; Mcmahon DK; Mellors JW; Tebas P; Gandhi RT; J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e27-e31. PubMed ID: 31335587 [TBL] [Abstract][Full Text] [Related]
14. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879 [TBL] [Abstract][Full Text] [Related]
15. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577 [TBL] [Abstract][Full Text] [Related]
16. Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection. Naidoo KK; Ndumnego OC; Ismail N; Dong KL; Ndung'u T Front Immunol; 2021; 12():738743. PubMed ID: 34630420 [TBL] [Abstract][Full Text] [Related]
17. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression. Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735 [TBL] [Abstract][Full Text] [Related]
18. Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy. Scherpenisse M; Kootstra NA; Bakker M; Berkhout B; Pasternak AO mBio; 2021 Mar; 12(2):. PubMed ID: 33688002 [TBL] [Abstract][Full Text] [Related]
19. Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals. El-Diwany R; Breitwieser FP; Soliman M; Skaist AM; Srikrishna G; Blankson JN; Ray SC; Wheelan SJ; Thomas DL; Balagopal A AIDS; 2017 Jun; 31(10):1405-1414. PubMed ID: 28358734 [TBL] [Abstract][Full Text] [Related]
20. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease. Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]